DeutschNewstral
Article
pressherald.com on 2021-12-08 22:34
Biogen’s $56 000 Alzheimer’s drug evades Biden’s cost curbs
Related news
$56K Alzheimer’s drug avoiding Biden’s cost curbs, for nowStar Telegram
$56K Alzheimer’s drug avoiding Biden’s cost curbs, for now - Wed, 08 Dec 2021 PSTThe Spokesman-Review
FDA approves Biogen’s controversial Alzheimer’s drugNew York Post- FBiogen’s Alzheimer’s drug shows early promiseft.com
Report
Biogen’s Alzheimer’s drug shows early promiseReuters- BBiogen’s Alzheimer’s Drug Won’t Get Approved, Analyst Saysbarrons.com
- BAnother Setback for Biogen’s Controversial Alzheimer’s Drug1 min readbarrons.com
- Biogen’s controversial Alzheimer’s drug made $1.6M in revenue in JuneNew York Post
- BBiogen’s Alzheimer’s Drug Has Another Shot at Success3 min readbarrons.com
- BSigns Point to FDA Approval for Biogen’s Alzheimer’s Drugbarrons.com
Analysts see new hope for approval of Biogen’s Alzheimer’s drugbizjournals.com
Biogen’s New Alzheimer’s Drug Beyond Reach for Many Patientswsj.com- Biogen’s Alzheimer’s Drug Won’t Be Covered by VA Health Systemwsj.com
- FBiogen’s Japanese partner calls for global action on Alzheimer’sft.com